Abstract: The invention provides isolated nucleic acids molecules, designated GL50 nucleic acid molecules, which encode novel GL50 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing GL50 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GL50 gene has been introduced or disrupted. The invention still further provides isolated GL50 polypeptides, fusion proteins, antigenic peptides and anti-GL50 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
Type:
Application
Filed:
December 19, 2005
Publication date:
May 11, 2006
Applicant:
Genetics Institute, LLC
Inventors:
Vincent Ling, Kyriaki Dunussi-Joannopoulos
Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
Type:
Application
Filed:
January 5, 2006
Publication date:
May 11, 2006
Applicants:
The United States of America as represented by the Secretary of the Navy, The Regents of the University of Michigan, Genetics Institute, LLC
Inventors:
Carl June, Craig Thompson, Gary Nabel, Gary Gray, Paul Rennert
Abstract: Provided by the present invention are novel compositions and methods for obtaining concentrated preparations of IL-11 and formulations of IL-11 suitable for storage and administration.
Type:
Grant
Filed:
October 5, 2001
Date of Patent:
April 25, 2006
Assignee:
Genetics Institute LLC
Inventors:
Nicholas W. Warne, Rebecca L. Ingram, Shannon Macmillan
Abstract: Novel polypeptides of human megakaryocyte stimulating factors (MSFs). Pharmaceutical compositions containing same, and methods for their preparation and use are provided.
Type:
Grant
Filed:
April 16, 2002
Date of Patent:
April 18, 2006
Assignee:
Genetics Institute LLC
Inventors:
Katherine Turner, Steven C. Clark, Kenneth Jacobs, Rodney M. Hewick, Thomas G. Gesner
Abstract: Purified human SDF-5 proteins and processes for producing them are disclosed. DNA molecules encoding the human SDF-5 proteins are also disclosed. The proteins may be used in regulating the binding of Wnt genes to their receptor. In preferred embodiments, the proteins may be used for inducing formation, growth, differentiation, proliferation and/or maintenance of chondrocytes and/or cartilage tissue, and for other tissue repair, such as pancreatic tissue repair.
Type:
Grant
Filed:
October 15, 1997
Date of Patent:
April 11, 2006
Assignee:
Genetics Institute, LLC
Inventors:
Edward R. LaVallie, Lisa A. Racie, Gary Hattersley
Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
Type:
Application
Filed:
January 4, 2005
Publication date:
January 19, 2006
Applicants:
The United States of America as represented by the Secretary of the Navy, The Regents of the University of Michigan, Genetics Institute, LLC.
Inventors:
Carl June, Craig Thompson, Gary Nabel, Gary Gray, Paul Rennert
Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
Type:
Grant
Filed:
July 27, 2000
Date of Patent:
January 10, 2006
Assignee:
Genetics Institute, LLC
Inventors:
Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2-Gamma enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
Type:
Grant
Filed:
July 8, 2002
Date of Patent:
December 27, 2005
Assignee:
Genetics Institute, LLC
Inventors:
Chuanzheng Song, Ronald Kriz, John Knopf
Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
Type:
Grant
Filed:
February 12, 1999
Date of Patent:
December 6, 2005
Assignee:
Genetics Institute, LLC
Inventors:
Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
Abstract: The invention provides methods for identifying, designing, and optimizing therapeutics for R.A using as targets one or more genes (and/or their encoded gene products) that have been shown to be up- or down-regulated in cells of R.A. relative to normal counterpart cells. Methods and compositions for diagnostic assays for detecting R.A. are also provided.
Type:
Application
Filed:
December 16, 2004
Publication date:
November 3, 2005
Applicant:
Genetics Institute, LLC
Inventors:
Debra Pittman, Jeffrey Feldman, Kathleen Shields, William Trepicchio
Abstract: Polynucleotides encoding human CTLA-8 (now known as IL-17F) and related proteins are disclosed. Human CTLA-8 and related proteins, including anti-human IL-17F antibodies, and methods for their production are also disclosed. Methods of treatment using human CTLA-8 and related proteins, rat CTLA-8 proteins and herpes CTLA-8 proteins are also provided.
Type:
Application
Filed:
January 14, 2005
Publication date:
September 29, 2005
Applicant:
GENETICS INSTITUTE, LLC
Inventors:
Kenneth Jacobs, Kerry Kelleher, McKeough Carlin, Samuel Goldman, Debra Pittman, Sha Mi, Steven Neben, Joanne Giannotti, Margaret Golden-Fleet
Abstract: Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.
Type:
Grant
Filed:
February 25, 2002
Date of Patent:
September 6, 2005
Assignee:
Genetics Institute, LLC
Inventors:
Kenneth Jacobs, Debra D. Pittman, Lynette Fouser, Vikki Spaulding, Dejun Xuan
Abstract: The present invention provides a process for isolating and purifying highly anionic target proteins, for example, sulfated proteins. Sulfated proteins have five (5) or more, sulfations. In a preferred embodiment, the sulfated protein has six (6) sulfations, e.g., six sulfations on N-terminal tyrosine residues, as embodied in PSGL-1 (P-selectin glycoprotein ligand).
Type:
Grant
Filed:
March 27, 2001
Date of Patent:
August 23, 2005
Assignee:
Genetics Institute, LLC
Inventors:
Jonathan L. Coffman, William Barry Foster, Bonnie J. Germain, Shujun Sun, Jeffrey J. Robinson
Abstract: The invention provides isolated nucleic acids molecules, designated SLIC-1 nucleic acid molecules, which encode novel P-selectin glycoprotein ligand (PSGL-1) binding molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing SLIC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a SLIC-1 gene has been introduced or disrupted. The invention still further provides isolated SLIC-1 proteins, fusion proteins, antigenic peptides and anti-SLIC-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
Type:
Application
Filed:
October 12, 2004
Publication date:
July 14, 2005
Applicant:
Genetics Institute, LLC
Inventors:
Meike Lorenz, Ron Kriz, Nadine Weich, Gray Shaw
Abstract: Novel compounds are disclosed which inhibit the activity of phospholipase enzymes in a mammal, particularly cytosolic phospholipase A2. Pharmaceutical compositions comprising such compounds and methods of treatment using such compositions are also disclosed.
Type:
Grant
Filed:
May 8, 2002
Date of Patent:
July 12, 2005
Assignee:
Genetics Institute, LLC
Inventors:
Jasbir S. Seehra, Neelu Kaila, John C. McKew, Frank Lovering, Jean E. Bemis, YiBin Xiang
Abstract: Tumor cells modified to express one or more T cell costimulatory molecules are disclosed. Preferred costimulatory molecules are B7-2 and B7-3. The tumor cells of the invention can be modified by transfection with nucleic acid encoding B7-2 and/or B7-3, by using an agent which induces or increases expression of B7-2 and/or B7-3 on the tumor cell or by coupling B7-2 and/or B7-3 to the tumor cell. Tumor cells modified to express B7-2 and/or B7-3 can be further modified to express B7. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor.
Type:
Application
Filed:
January 28, 2004
Publication date:
June 16, 2005
Applicants:
GENETICS INSTITUTE, LLC., Dana-Farber Cancer Institute, Inc.
Abstract: Polynucleotides encoding human CTLA-8 (now known as IL-17F) and related proteins are disclosed. Human CTLA-8 and related proteins, including anti-human IL-17F antibodies, and methods for their production are also disclosed. Methods of treatment using human CTLA-8 proteins, rat CTLA-8 proteins and herpes CTLA-8 proteins are also provided.
Type:
Grant
Filed:
March 19, 2002
Date of Patent:
June 7, 2005
Assignee:
Genetics Institute, LLC
Inventors:
Kenneth Jacobs, Kerry Kelleher, McKeough Carlin, Samuel Goldman, Debra Pittman, Sha Mi, Steven Neben, Joanne Giannotti, Margaret M. Golden-Fleet
Abstract: Antibodies to IL-1-R intracellular ligand proteins are disclosed. The antibodies arc useful for inhibiting the binding between IL-1-R and IL-1-R intracellular ligand proteins.
Abstract: Polynucleotides encoding DADD protein are also disclosed, along with vectors, host cells, and methods of making DADD protein. Methods of identifying inhibitors of DADD death domain binding and inhibitors identified by such methods are also disclosed.